Acadia Pharma (ACAD) Phase 3 ENHANCE Trial of Pimavanserin Did Not Achieve Primary Endpoint
Tweet Send to a Friend
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
